Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of circ-SLC38A1 as target point in medicine for inhibiting bladder cancer cells

A technology of bladder cancer and drugs, applied in the field of tumor biological gene therapy, can solve the problems of bleeding and infection risks, low sensitivity, and low sensitivity of carcinoma in situ diagnosis

Active Publication Date: 2020-12-01
THE SECOND HOSPITAL OF SHANDONG UNIV
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Currently, cystoscopy and urine cytology are the main diagnostic methods for bladder cancer clinically. However, cystoscopy is an invasive test with risks of bleeding and infection, and has low sensitivity for the diagnosis of carcinoma in situ.
Urine cytology is prone to false positive results due to the influence of stones and inflammation, and the sensitivity is also very low

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of circ-SLC38A1 as target point in medicine for inhibiting bladder cancer cells
  • Application of circ-SLC38A1 as target point in medicine for inhibiting bladder cancer cells
  • Application of circ-SLC38A1 as target point in medicine for inhibiting bladder cancer cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] 5 cases of bladder cancer and 5 adjacent normal tissues were selected from the tissue sample bank. After the RNA library was prepared and passed the quality inspection, the Illumina Hiseq4000 sequencing platform was used for high-throughput and deep sequencing in PE150 sequencing mode, and the signal data were processed (significant differences in settings The default threshold of the gene is: p≤0.05 and Fold change≥2.0), and 2196 circRNAs with significant differential expression were obtained, of which 1797 showed up-regulated expression and 399 showed down-regulated expression. The differentially expressed circRNAs were clustered and analyzed, and According to GO and KEGG differential circRNA functional enrichment analysis, the expression of circ-SLC38A1 (has_circ_0000396) was significantly upregulated in bladder cancer tissues.

[0036] By designing specific primers capable of amplifying the circular RNA, and determining the accurate circularization site of circ-SLC38...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of tumor biological gene therapy, and relates to a bladder cancer diagnosis and treatment biomarker and a target spot, in particular to application of circ-SLC38A1 as a target spot in a bladder cancer cell inhibition medicine. The invention discloses an expression condition of circ-SLC38A1 in tumor tissues of a bladder cancer patient and a function of circ-SLC38A1 in bladder cancer cells. It is found for the first time that circ-SLC38A1 can be used as a bladder cancer diagnosis biomarker and a drug therapy target. Compared with normal control, circ-SLC38A1 is significantly up-regulated in tumor tissues of bladder cancer patients. The result of the invention shows that interference on circ-SLC38A1 can inhibit the migration and invasion ability ofbladder cancer cells, and it is shown that the circ-SLC38A1 plays a role of a cancer-promoting gene in the occurrence and development of bladder cancer, and provides a new target for clinical treatment of bladder cancer.

Description

technical field [0001] The invention belongs to the technical field of tumor biological gene therapy, and relates to a biological marker and a target for diagnosis and treatment of bladder cancer, in particular to the application of circ-SLC38A1 as a target in drugs for inhibiting bladder cancer cells. Background technique [0002] Bladder cancer (BC) is the most common malignant tumor of the urinary system and one of the ten most common tumors in the whole body. It accounts for the first place in the incidence of urogenital tumors in my country, and ranks second in the West after prostate cancer. In 2012, the incidence rate of bladder cancer in the national tumor registration area was 6.61 / 100,000, ranking ninth in the incidence rate of malignant tumors. Bladder cancer can occur at any age, even in children, and the incidence and mortality of cancer have continued to rise in recent decades. About 25% of urothelial carcinomas are diagnosed as muscle-invasive bladder cancer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12N15/113A61K31/713A61P35/00
CPCA61K31/713A61P35/00C12Q1/6886C12Q2600/158C12Q2600/178
Inventor 杜鲁涛王传新李培龙米琦齐秋晨李娟
Owner THE SECOND HOSPITAL OF SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com